Effect of early administration of dexamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome: EARLY-DEX COVID-19 trial

Effect of early administration of dexamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome: EARLY-DEX COVID-19 trial

Introduction and objectivesCorticosteroids are among the drugs demonstrating a mortality benefit for coronavirus disease 2019 (COVID-19). The RECOVERY trial highlighted that dexamethasone reduced 28-day mortality for hospitalized COVID-19 patients requiring either supplemental oxygen or mechanical v...

Full description

Bibliographic Details
Main Authors: Anabel Franco-Moreno, María Soledad Acedo-Gutiérrez, Miguel Ángel Casado-Suela, Nicolás Labrador-San Martín, María de Carranza-López, Fátima Ibáñez-Estéllez, Clara Hernández-Blanco, José Jiménez-Torres, Ignacio Vallejo-Maroto, Rodolfo Romero-Pareja, Gabriela Peña-Lillo, Ismael Escobar-Rodríguez, Juan Torres-Macho, EARLY-DEX COVID-19 Research Group, Belén Escolano-Fernández, Nuria Alfaro-Fernández, Mateo Balado-Rico, Ana Rocío Romero-Paternina, Esther Piniella-Ruiz, Ester Alonso-Monge, Helena Notario-Leo, Carlos Bibiano-Guillén, Armando Antiqueira-Pérez, Noemí Cabello-Clotet
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-07-01
Series:Frontiers in Medicine
Subjects:
acute respiratory distress syndrome
biomarkers
COVID-19 management
dexamethasone
inflammation
mortality
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2024.1385833/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2024.1385833/full

Similar Items